Seagen Inc.
Methylene Carbamate Linkers for use with Targeted-Drug Conjugates
Last updated:
Abstract:
The present invention provides Ligand-Drug Conjugates and Drug-Linker Compounds comprising a methylene carbamate unit. The invention provides inter alia, Ligand-Drug Conjugates, wherein the Ligand-Drug Conjugate is comprised of a Self-immolative Assembly Unit having a methylene carbamate unit for conjugation of a drug to a targeting ligand, methods of preparing and using them, and intermediates thereof. The Ligand-Drug Conjugates of the present invention are stable in circulation, yet capable of inflicting cell death once free drug is released from a Conjugate in the vicinity or within tumor cells.
Status:
Application
Type:
Utility
Filling date:
2 Aug 2021
Issue date:
24 Feb 2022